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ABSTRACT 
Objective: Previous studies have indicated that dysregulation of miRNAs in visceral 
adipose tissue of mice and omental/subcutaneous adipose tissue of humans are linked 
to obesity and insulin resistance. In this study, we profile the differential miRNA 
expression of obese IR bariatric patients and propose mechanisms of miRNA transport 
that may play a role in systemic inflammation/insulin resistance. 
Methods and Results: Whole visceral adipose tissue from lean and obese patients 
undergoing bariatric surgery was analyzed for miRNA expression. Four miRNAs (miR-
223, miR-486, miR-15b, and miR-451) were upregulated in obese patients and found to 
be overexpressed in the stromal vascular fraction (SVF) of the visceral adipose tissue. 
The overexpression of miR-223 in the SVF was also confirmed in a mouse model. 
Expression of miR-223 was found to be upregulated in mouse liver tissue, but not in 
mouse muscle tissue, human blood monocytes, or human adipocytes. Isolation of 
human plasma exosomes revealed miR-223 was selectively overexpressed relative to 
the other three miRNAs. 
Conclusions: In this paper, we profile previously unreported obesity-related miRNA 
upregulation in the stromal vascular fraction of human visceral adipose tissue. Our 
results provide evidence that miRNA dysregulation during chronic obesity may play a 
key role in regulation of inflammation and insulin resistance of not only adipose tissue 
but of other tissues as well. We also show preferential enrichment of miR in the plasma 
exosome compartment and introduce the possibility of miRNA transport from viscera to 
distal metabolic organs. 
INTRODUCTION 
Chronic obesity represents a growing worldwide problem and is considered the 
sixth most important risk factor contributing to overall burden of disease [1]. Impacts on 
life expectancy due to obesity have namely been attributed to development of 
cardiovascular diseases and type 2 diabetes. However, obesity also results in a wide 
variety of pathophysiological conditions including insulin resistance, glucose intolerance, 
systemic inflammation, and metabolic disorders [1,2,3].  
Obesity-related visceral adipose tissue changes include a significant infiltration of 
inflammatory immune cells (T cells and macrophages), adipocyte hypertrophy, and 
increased adipocyte cell death. Infiltrating macrophages and T-cells secrete 
inflammatory cytokines and the resulting inflammatory effects within adipose tissue 
have been well documented [4,5,6,7]. Using mouse models, the role of inflammatory 
cells / visceral adipose inflammation has been shown to be etiologically relevant in diet-
induced obesity (DIO) and insulin resistance (IR) [8,9]. Understanding the pathogenic 
changes that occur in the visceral adipose during DIO is essential to developing 
effective therapeutics targeting IR/T2DM.  
MicroRNAs (miRNAs) are small, ~22 nucleotide, highly-conserved, non-coding 
strands of RNA thought to play an important role in post-transcriptional regulation of a 
variety of cellular processes in eukaryotic organisms [10]. By base-pairing with 
complimentary “seed” sites within target mRNAs, miRNAs can cause degradation of the 
mRNA strand or translational repression [11,12,13]. An estimated 30% of the human 
genome is thought to be regulated by miRNAs. Of particular interest for this study, 
miRNAs have been shown to play critical roles in regulation of adipogenesis, lipid 
metabolism, and inflammatory response [14,15]. Thus dysregulation of miRNAs in the 
obese state may  play a role in  visceral adipose inflammation and tissue dysfunction, 
potentiating metabolic disease development and/or progression.  
Previous studies have indicated that dysregulation of miRNAs in visceral adipose 
tissue of mice and omental/subcutaneous adipose tissue of humans are linked to 
obesity and insulin resistance [16,17]. In particular, one study analyzed miRNA 
modulation after DIO in mice and found 22 differentially-expressed miRNAs compared 
to lean counterparts [18]. Further studies have identified dysregulation of miRNAs in 
subcutaneous and visceral adipose tissue of non-obese hyperglycemic individuals when 
compared to non-obese normoglycemic individuals [19]. Evidence suggests that 
adipose tissue miRNA dysregulation is linked to obesity and insulin resistance, 
especially in mouse models.  
In this study, we profile the differential miRNA expression of obese IR bariatric 
patients. Moreover, we show conservation of miRNA regulation in a mouse model by 
analyzing adipose, liver, and muscle tissue. We show preferential enrichment of miR in 
the plasma exosome compartment and introduce the possibility of miRNA transport 
from viscera to distal metabolic organs. 
 
METHODS AND MATERIALS 
Human Participants 
Visceral adipose tissue was obtained from the greater omentum of patients 
undergoing hernia repairs or bariatric surgery. Patients were stratified based on BMI 
(lean, BMI<30; obese, BMI≥40). Fasting blood was drawn the morning of surgery by 
venipuncture and plasma isolated using centrifugation. The Office of Responsible 
Research Practices, Human Institutional Review Board (IRB) of the Ohio State 
University under OSU protocol #2008H0177, has approved this study and its 
procedures. Human informed consent was obtained. 
Human Tissue Processing 
A portion of whole adipose sample was digested using collagenase and 
separated by centrifugation into stromal vascular fraction (SVF) and adipocyte/fat 
fraction (FF). The SVF, containing macrophages, monocytes, T-cells, B-cells, and 
endothelial progenitor cells—were lysed in TRIzol® reagent (Life Technologies) and 
frozen at -80° C until needed. The adipocyte fraction (FF) was frozen separately at -80° 
C. 
Mouse Tissue 
Previously banked mouse muscle, liver, and adipose tissue from ob/ob knockout 
mice (a genetic model of spontaneous obesity) and wild-type (WT) C57BL/6 controls 
were analyzed. The samples were from obesity experiments previously performed in the 
lab.   
RNA Isolation 
Prior to RNA isolation, tissue was homogenized in one milliliter TRIzol® reagent 
before lipids were removed via centrifugation. To extract RNA, chloroform (200 µl) was 
added to samples containing TRIzol. Centrifugation (12,000 x g, 15 min, 4° C) 
separated aqueous and organic layers.  RNA was precipitated from the aqueous layer 
using isopropyl alcohol. Linear acrylamide was used to increase RNA yield. The RNA 
pellet was washed in ethanol before air drying.  RNA was dissolved in RNase free water 
and quantified using Nanodrop microvolume spectrophotometer (Thermo Scientific). 
Purity of samples was determined by 260/280 and 260/230 ratios which measure DNA 
and protein contamination, respectively. RNA was stored at -80°.  
Exiqon miRNA Analysis 
1 µg of RNA from human whole visceral adipose was hybridized to an Exiqon 
miRCURY™ LNA Array 5th generation (product number 208300-A (208301-A / 208302-
A, slide batch 33011) using miRBase 15.0 + miRPlus. Analysis of the scanned slides 
showed that the labeling was successful as all capture probes for the control spike-in 
oligo nucleotides produced signals in the expected range. The quantified signals 
(background corrected) were normalized using the global Lowess (LOcally WEighted 
Scatterplot Smoothing) regression algorithm. In the expression matrix, all capture 
probes with both Hy3 (sample) and Hy5 (common reference pool) signals lower than 
1.5x of the median signal intensity of the given slide were excluded from analysis. Only 
log2(Hy3/Hy5) ratios which passed the filtering criteria on variation across samples 
were used. Student’s t-test was performed between lean and obese patient groups. The 
miRNAs with mean expression level change above 1.3-fold, and p value < 0.05 were 
further selected to check their correlation with patient phenotypic traits (BMI, CRP level, 
fasting insulin level, and HOMA index). 
RT PCR for miRNA-Specific cDNA 
MicroRNA specific cDNA was generated via the ABI TaqMan MicroRNA Reverse 
Transcription Kit (Applied Biosystems). Briefly, 1 µl of 10X Reverse Transcriptase buffer, 
0.75 µl of 10mM DNTPs, 0.5 µl of Reverse Transcriptase enzyme, 0.09 µl of RNase 
inhibitor, and 1.5 µl of microRNA specific primer were used to create a 3.84 µl RT 
master mix per sample. Then, 6.16 µl of RNA sample at 1 ng/ µl was added to the 
master mix to create a 10 µl reaction per sample. Samples were loaded into a 
thermocycler and reverse transcription reaction as described by the manufacturer was 
performed. Resulting microRNA cDNA samples were kept frozen at -80° C until needed.  
qPCR Assay for miRNA cDNA 
Quantitative PCR via ABI Taqman Probe Assay (Applied Biosystems) was 
performed to measure expression of target microRNAs in the tissue samples relative to 
a reference snRNA (RNU44). ABI Taqman Probe master mix (5.0 µl per reaction) mixed 
with 20X microRNA specific probe (0.5 µl per reaction) was used alongside 4.5 µl of 
microRNA specific cDNA to create a 10 µl reaction. Each sample was tested in 
duplicate. Expression of microRNA was quantified via fold change relative to RNU44. 
 
 
RT PCR for Total cDNA 
Total cDNA was generated from each RNA sample in order to test for gene 
expression. Briefly, a 5.0 µl master mix reaction composed of 1.0 µl of 10X RT Buffer, 
1.0 µl of 10mM DNTPs, 1.0 µl of 10X ABI Random Primers (Applied Biosystems), 0.5 µl 
of Reverse Transcriptase enzyme, and 1.5 µl of RNase free H20 was used per sample. 
Then, 350 ng of total RNA in a total volume of 5.0 µl H20 was added to the master mix 
to create a 10 µl reaction per sample. Samples were loaded into a thermocycler and 
reverse transcription reaction was performed as per the manufacturers directions. 
Resulting total cDNA samples were kept frozen at -80° C until needed. 
qPCR for Gene Expression 
Quantitative PCR via SYBR Green Assay (Integrated Technologies) was 
performed to measure relative gene expression in tissue samples. Reactions consisting 
of 5.0 µl of SYBR Green master mix, 0.1 µl each of Forward and Reverse Primer, and 
5.0 µl of total cDNA from samples were performed in duplicate per sample. Gene 
expression is expressed as fold change relative to B-actin housekeeping gene. 
Isolation of Plasma Exosomes 
Plasma was isolated from freshly collected EDTA-anti-coagulated blood. 
Differential centrifugation (16,500xg, 20”; 0.22 um filtration; 120,000xg, 180”) yielded 
secreted microvesicles (exosomes 50-200nm in size) and lipoproteins. RNA was 
isolated from exosomal pellet via Exiqon miRCURY™ RNA isolation kit. miR-specific 
cDNA was synthesized using equal volumes of RNA. miRNA expression was quantified 
by miRNA qPCR analysis as previously described.  
RESULTS 
Exiqon Array Profiling of Patients 
Exiqon array data was analyzed by a consulting bioinformatics specialist who 
determined that 12 microRNAs passed the threshold of mean fold change > 1.3 and p-
value < 0.05 between the lean and obese groups with three microRNAs being down-
regulated (miR-299-3p, miRPlus-E1067, and miRPlus-E1076) and nine up-regulated 
(miR-202, -15b, -451, -24-2*, 1184, -187*, -486-5p, -10b, and -223). Hierarchical bi-
clustering organized patients independent of group, re-arranging both axes by the 
correlation of expression profiling patterns (Figure 1). Hierarchical bi-clustering 
separated lean (blue) and obese (black) samples to groups relatively faithfully, with the 
exception of patient V28 and V14. Biomorphic characteristics of the sample population 
used in this experiment are shown in Table 1. Pearson correlation calculations were 
performed between data obtained from adipose tissue microRNA expression profiling 
and BMI, fasting insulin, CRP, and HOMA-IR. Of particular interest for this study were 
miR-223, mir-451, mir-15b, and mir-486, all of which correlated highly to the analyzed 
biomarkers (Table 2). 
 Table 1. Biomorphic comparison of patients for Exiqon analysis 
 Lean	   Obese 
Age 41.7±6 47.6±5 
Gender 4F; 2M 5F; 1M 
BMI 27±0.6 50±3* 
Glucose 90±10 143±20* 
Insulin 3.4±1.2 19.3±3.1* 
HOMA-IR 0.77±0.3 6.7±1.3* 
QUICKI 0.43±0.02 0.29±0.01* 
HemA1c 5.6±0.1 6.6±1 
TG 123±31 144±32 
CRP 2.4±0.8 8.3±3.4 
TC 171±9 168±14 
HDL 44±4.3 41±7.5 
Figure 1. Heirarchial biclustering of heatmap data of 12 significantly changed miRNAs 
automatically clusters lean and obese groups. This is indicative of correlation between 
miRNAs and obesity.
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Table 2. Pearson correlation coefficients of significant correlations between miRNA 
expression and the patient phenotypical traits. 
miR BMI Fasting Insulin HOMA CRP 
miR-223 0.80 p=0.002 0.66 p=0.027  0.63 p=0.038 
miR-486-5p 0.74 p=0.006 0.72 p=0.013 0.70 p=0.016 0.68 p=0.021 
miR-451 0.74 p=0.006 0.61 p=0.047 0.61 p=0.044 0.61 p=0.046 
miR-15b 0.74 p=0.006 0.67 p=0.023 0.66 p=0.028 0.62 p=0.040 
 
Determining the source of obesity-related miR-223 expression 
 To determine which fraction of adipose tissue is responsible for increases of miR-
223 expression, lean (n=7) and obese (n=7) stromal vascular fraction (SVF) and fat 
fraction (FF) samples from the same patients were analyzed via qPCR for expression of 
miR-223. A significant increase in miR-223 expression was observed in the SVF obese 
samples (4.9-fold increase, p-value < 0.05) relative to SVF lean samples (Figure 2A). 
However, no difference was observed between the lean and obese groups in the FF 
samples relative to each other or relative to SVF lean samples. This indicates that SVF 
fraction is responsible for the observed increases in miR-223. Expression of miR-223 in 
monocytes isolated from patient blood samples were also analyzed (Figure 2B). No 
difference was found in these samples. 
  
qPCR Verification of Exiqon Data  
Quantitative PCR analysis of RNA isolated from the SVF of lean and obese 
patients indicates there is a significant (p-value < 0.05) upregulation of mir223 (3.3-fold 
increase), mir15b (2.4-fold increase), mir451 (2.4-fold increase), and mir486 (2.3-fold 
increase) in obese patients when compared to their lean counterparts (Figure 3). These 
results were confirmed in replicate experiments. RNU44 was used as the housekeeping 
miRNA in these experiments. Biomorphic characteristics of the sample population used 
in this experiment are shown in Table 3.  
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Figure 2. Quantitative PCR was used to measure miR-223 expression in SVF and FF of both lean 
and obese patients (A). Fold change is expressed relative to levels of SVF LN. The same patients 
used for SVF LN and OB were also used in the FF LN and OB. n=7 for each LN and OB group. 
Expression of miR-223 was also analyzed in blood monocytes. No difference was found.
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Table 1. Biomorphic comparison of patients used for qPCR analysis 
 Lean	   Obese 
Age 47.1±15 44.3±10 
Gender 9F;10M 10F; 9M 
BMI 25.1±2 52.1±8* 
Glucose 88±8 132±36* 
Insulin 4.5±2.8 17.1±12* 
HOMA-IR 1.0±0.6 5.8±5* 
QUICKI 0.4±0.04 0.3±0.05* 
HemA1c 5.4±0.4 6.1±1 
TG 86±74 124±56 
CRP 2.0±2.8 8.2±5.4 
TC 173±54 163±29 
HDL 52±16 37±7.5* 
LDL 103±47 101±28 
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Figure 3. Relative miR-223 (A), miR-486 (B), miR-15b (C), and miR-451 (D) expression in SVF 
of lean and obese patients was measured via ABI TaqMan Probe qPCR kit. RNU44 was used 
as the houskeeping gene. 
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miR-451 is Highly Expressed in SVF  
Quantitative PCR was used to analyze expression all four microRNAs of interest 
(mir223, mir451, mir15b, mir486) relative to each other in SVF samples (n=3). This was 
achieved by running reactions on one plate and normalizing fold difference relative to 
the lowest expressed microRNA, as identified by CT value. These reactions were run in 
duplicate. Mir-451 is expressed over 40 times higher than the other microRNAs of 
interest (Figure 4). This dramatic difference in expression suggests a more important 
physiological role for mir451. 
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Figure 4. Quantative PCR was used to assess relative expression levels of microRNAs of 
interest in the SVF. Fold change is expressed relative to miR-486 expression levels (i.e. 
miR-486 fold change is 1). For each microRNA, n=3. Same patient samples were used for each 
microRNA
miR-486 Gene Target Expression unchanged in human samples 
 Quantitative PCR via SYBR Green was performed on SVF LN and OB samples 
to test for expression of SIRT-1, a putative gene target of miR-486 and an important 
glucose mediated cell cycle regulator [19]. No change was observed in gene expression 
between lean and obese patients (Figure 5). Thus any observed changes in SIRT-1 
protein expression or SIRT-1 activity may be due to post-transcriptional regulation as is 
the case for most miRNA regulated genes. 
Mouse Model Corroborates miR-223 Differential Expression 
 RNA isolated from ob/ob and WT mouse whole visceral adipose tissue was 
analyzed for miR-223 expression. There was a 2-fold increase in miR-223 expression in 
the ob/ob mouse adipose tissue when compared to wild-type counterparts. Furthermore, 
analysis of liver tissue found a 3-fold increase in miR-223 expression in ob/ob mice. 
These data suggest that the liver may play a vital role in miR-223-modulated insulin 
resistance. Analysis of muscle tissue from ob/ob and WT mice found no difference in 
miR-223 expression (Figure 6). 
 Plasma Exosomes Derived from Obese humans are preferentially enriched in 
miR-223 
 Exosomal RNA isolated from plasma was analyzed for miRNAs of interest via 
ABI TaqMan Probe qPCR. All miRNAs of interest (miR-223, miR-451, miR-15b, miR-
486) were expressed in the exosomes (Figure 7A). However, only miR-223 was 
differentially expressed between lean and obese samples. There was approximately a 
9-fold (p-value < 0.05) increase of miR-223 expression in obese samples compared to 
lean samples (Figure 7B). 
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Figure 6. qPCR analysis reveals significant increase in miR-223 expression in 
adipose and liver tissue of ob/ob mice when compared to the WT control. n=8/group
miRNA Expression in Exosomes
m
iR
-2
23
/1
.5
 m
l o
f p
la
sm
a 
(C
t V
al
ue
)
mi
R-
48
6
mi
R-
15
b
mi
R-
45
1
mi
R-
22
3
0
10
20
30
40
Lean
Obese
Relative miR-223 Expression in Exosome
LN OB
0
5
10
15
Fo
ld
 C
ha
ng
e
LN
OB
Figure 7. miR-486, miR-15b, miR-451, and miR-223 are all expressed in exosomes isolated from 
human plasma (A). miR-223 expression is increased 9-fold in the exosomes.
DISCUSSION 
In this study we profile miRNAs in human adipose tissue that are differentially 
expressed in lean and obese patients. We then used a mouse model to confirm that this 
expression is conserved. Our results provide evidence that miRNA dysregulation during 
chronic obesity may play a key role in regulation of inflammation and insulin resistance 
of not only adipose tissue but of other tissues as well. 
Exiqon data showed significantly increased expression of miR-223, miR-486, 
miR-451, and miR-15b in in the visceral adipose tissue of obese patients compared to 
their lean counterparts. Pearson correlation curves indicated that all four miRNAs have 
strong correlations with BMI, fasting insulin, and C-reactive protein and all but miR-223 
have a strong correlation to HOMA-IR. These correlations suggest that expression of 
the miRNAs is correlated with obesity (as measured by BMI), insulin resistance (as 
measure by fasting insulin and HOMA-IR), and inflammation (as measure by C-reactive 
protein). Because of the correlations of these four miRNAs to relevant biomarkers, we 
pursued further analysis to characterize their adipose expression. 
We determined that miR-223 was differentially expressed in the SVF of lean and 
obese patients but not in the FF or the blood monocytes. SVF is primarily composed of 
a mixed population of monocytes, macrophages, T-cells, and pre-adipocytes. Thus, the 
data suggests that this population of cells is solely responsible for the upregulation of 
miR-223 expression in the whole adipose rather than adipocytes which are primarily 
found in the FF. Based on previous studies, these results were expected. Recent 
studies have implicated miR-223 as critical regulator of macrophage activation. Putative 
gene targets of miR-223 suggest that this miRNA plays a central role in regulation of 
ubiquitination/protein degradation (via FBXw7) and insulin signaling (via IRS-1) [19] 
miR-223 has also been shown to be highly expressed in myeloid cell populations [20].  
Because miR-223 was highly expressed in SVF as opposed to FF, and because 
the other miRNAs of interest have previously been found in cells that comprise the SVF, 
we tested the SVF of a larger population of human samples for miRNA expression. Our 
results corroborated the Exiqon differential expression of miRNAs. Comparing relative 
expression levels of the miRNAs in the SVF found that miR-451 was much more highly 
expressed in the SVF than any other miRNA tested. This suggests that miR-451 may 
have a key pathophysiological role in adipose dysfunction. Evidence from previous 
studies indicate that miR-451 upregulation is induced by inflammatory cytokines such as 
IL-6 and type 1 Interferons [21]. Furthermore, miR-451 overexpression in gliomas have 
resulted in a downstream reduction of PI3K/AKT signaling [22]. This pathway is central 
to cell growth, apoptosis, and proliferation. Thus the high miR-451 expression found in 
the SVF could potentially be related to key role that miR-451 plays in overall cell 
function. Moreover, increases in miR-451, as is the case with the obese group, could 
result in apoptosis—not only potentiating inflammation of the visceral adipose tissue but 
also significantly contributing to adipose dysfunction. 
Our mouse model studies not only indicate that obesity related miR-223 
expression increase is a conserved finding in adipose tissue but that miR-223 
expression is also increased in other tissue. It is important to note that increased miR-
223 expression in the liver as a result of chronic obesity has not been previously 
described. The liver is a key organ in glucose metabolism  and is rich in innate immune 
cells. miR-223 dysregulation within this organ could result in changes in pathways 
relevant to DIO-IR. 
Our study reveals that miR-223 is expressed in both adipose and liver tissue and 
previous studies have shown that miR-223 is expressed in mouse macrophages (both 
bone marrow derived and cell lines) as well as human hepatic cell lines. However, 
obesity induced differential miR-223 expression seems to be localized to specific 
tissues and cannot be found in circulating blood monocytes. Thus we proposed a novel 
mechanism of miR-223 obesity related modulation of insulin sensitivity via a visceral 
adipose tissue derived, miR-223 rich, exosome delivery to distant tissues. Our data 
shows a 9-fold increase in the expression of miR-223 in plasma derived exosomes thus 
providing preliminary evidence to support such a hypothesis. Exosomal delivery of 
miRNAs in general is not a novel mechanism. miRNA containing exosomes have been 
shown to exert paracrine-like effects in cardiovascular disease and cancer [23]. 
Macrophages have been known to regularly endocytose circulating exosomes and 
exosomal communication has been well characterized in immune systems [24,25].  
Exosomal transport of miR-223 derived from the visceral adipose could provide a 
direct link between localized and systemic inflammation/insulin resistance. The 
challenge in diabetes and obesity has always been to find mechanistic links between 
local and systemic regulation. Obesity in general is pathologically localized to deposits 
of adipose tissue. Resulting adipose dysfunction is also localized. However, if miR-223 
plays a central role in potentiating adipose dysfunction, then transport of miR-223 out of 
the adipose via exosomes provides a mechanistically sound link between local and 
systemic. Furthermore, miR-223 was found to be increased in the SVF. These cell 
population have direct access to the blood and thus transport of miR-223 by secreted 
exosomes can prove to be truly systemic in scope. The challenge now will be to provide 
more evidence of visceral adipose tissue derived miR-223 transport by increasing 
sample size and characterizing destinations of the miRNA.  Also, modulation of target 
genes needs to be analyzed to provide support to the idea that localized dysfunction 
can lead to systemic problems. Although the relative expression of the other miRNAs 
were not changed between lean and obese patients, this does not discount the potential 
for these miRNAs to play roles in adipose dysfunction or systemic problems. 
Although this study provides a compelling profile of miRNA modulation exhibited 
during chronic obesity, these data can only provide preliminary/hypothetical framework 
of mechanistic effects of miRNA dysregulation. Modulation of putative gene targets of 
these miRNAs as predicted by DIANA program has yet to confirmed. To this end, 3’ 
UTR luciferase assays need to be conducted for all miRNAs and target genes. Of 
particular interest and relevance is the canonical mTOR pathway that is involved in cell 
apoptosis, lipid metabolism, inflammation, and glucose metabolism. Furthermore, 
profiling of FF for all miRNAs can provide evidence to corroborate the data the suggests 
that SVF plays a much more significant role in the potentiation of adipose dysfunction 
and insulin resistance than FF. 
This study provides significant evidence for the multidimensional/multisystem role 
of miRNAs in chronic obesity. Current trends are shifting from viewing diseases as 
localized problems to being more systemically relevant with a centrally regulating 
mechanism. Specifically, obesity by itself is not a burdensome disease. However, 
development of insulin resistance, inflammatory diseases, type 2 diabetes, and 
cardiovascular diseases as a result of chronic obesity does create a significant burden. 
Finding the potential mechanisms of regulation of these systemic issues stemming from 
obesity—as we believe exosomal miR-223 transport may exhibit—can provide targets 
for drugs that provide a multisystem benefits. Furthermore, our mRNA profiling of 
chronically obese patients can provide other targets of interest for treating insulin 
resistance and preventing the development of type 2 diabetes. 
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